Literature DB >> 11745511

Quantitative analysis of mRNA expression of TIMPs in the periprosthetic interface tissue of loose hips by real-time PCR system.

K Sasaki1, M Takagi, J Mandelin, I Takei, S Santavirta, H Ida, T Ogino, Y T Konttinen.   

Abstract

Matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), have been reported to play a critical role in extracellular degradation around artificial hip joints. Although messenger ribonucleic acid (mRNA) expression patterns of several MMPs and TIMPs were reported, there is no report of quantitative mRNA analysis of TIMPs in periprosthetic tissues. In this study, mRNA expression of four different types of TIMPs in periprosthetic interface tissue of loose hips was analyzed by a quantitative polymerase chain reaction system. The mRNA expression level of TIMP-1, -2, and -3 in periprosthetic interface tissue was significantly higher than that in control. In contrast, the mRNA expression level of TIMP-4 in the periprosthetic interface tissue was lower. This study suggested that increased levels of TIMP-1, -2, and -3, and decreased levels of TIMP-4 may contribute to pathologic extracellular matrix degradation in combination with MMPs, thus leading to prosthetic loosening and osteolysis around artificial total hip joints. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745511     DOI: 10.1002/jbm.1059

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  8 in total

1.  Analysis of rheological properties of bone cements.

Authors:  M K D Nicholas; M G J Waters; K M Holford; G Adusei
Journal:  J Mater Sci Mater Med       Date:  2007-02-03       Impact factor: 3.896

2.  Expression of metalloproteinase 2 in the cell response to porous demineralized bovine bone matrix.

Authors:  Thais Accorsi-Mendonça; Willian Fernando Zambuzzi; Katiúcia Batista da Silva Paiva; José Roberto Pereira Lauris; Tânia Mary Cestari; Rumio Taga; José Mauro Granjeiro
Journal:  J Mol Histol       Date:  2005-05       Impact factor: 2.611

Review 3.  Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.

Authors:  Shahryar Noordin; Bassam Masri
Journal:  Can J Surg       Date:  2012-12       Impact factor: 2.089

4.  Enhanced expression of tissue inhibitor of metalloproteinases-4 gene in human osteoarthritic synovial membranes and its differential regulation by cytokines in chondrocytes.

Authors:  Wensheng Huang; Mohammed El Mabrouk; Judith Sylvester; Faramaze Dehnade; Muhammad Zafarullah
Journal:  Open Rheumatol J       Date:  2011-11-29

5.  Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma.

Authors:  Alexandra Fullár; Ilona Kovalszky; Mario Bitsche; Angela Romani; Volker Hans Schartinger; Georg Mathias Sprinzl; Herbert Riechelmann; József Dudás
Journal:  Exp Cell Res       Date:  2012-04-01       Impact factor: 3.905

6.  Genetic susceptibility of early aseptic loosening after total hip arthroplasty: the influence of TIMP-1 gene polymorphism on Chinese Han population.

Authors:  Fengyu Pan; Shan Hua; Yi Luo; Dongjun Yin; Zhuang Ma
Journal:  J Orthop Surg Res       Date:  2014-12-03       Impact factor: 2.359

7.  Contribution of human osteoblasts and macrophages to bone matrix degradation and proinflammatory cytokine release after exposure to abrasive endoprosthetic wear particles.

Authors:  Anika Jonitz-Heincke; Katrin Lochner; Christoph Schulze; Diana Pohle; Wera Pustlauk; Doris Hansmann; Rainer Bader
Journal:  Mol Med Rep       Date:  2016-06-21       Impact factor: 2.952

Review 8.  Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.

Authors:  Spyros A Syggelos; Alexios J Aletras; Ioanna Smirlaki; Spyros S Skandalis
Journal:  Biomed Res Int       Date:  2013-06-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.